Shares of Third Wave Technologies rose 8.4 percent for the five-day trading period ended Tuesday. The firm’s stock is up 17.7 percent since announcing on Dec. 5 that it had received the CE Mark for its HPV molecular diagnostic test, allowing it to sell the test throughout the European Union.
Qiagen led decliners for the week with a drop of 5.9 percent. Overall, 16 of the 21 stocks in the BCW Index lost value during the tracking period, and the Index closed down 1.1 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.